Mr. Nash: The company was founded in 1983 to exploit a technology called electroporation. It was not electroporation at the time, but is now a very widely used tool for getting materials ' proteins, genes and the like ' into the interior cells. So it's a physical drug delivery and cell manipulation company. We have two divisions: one division manufactures and sells products throughout the world that are used by PhD researchers in laboratories; the other division exploits this same technology of electroporation to deliver drugs and genes to people to cure disease. So we are a pure-play delivery system company, a 'toolę company in the vernacular of the healthcare industry.
TWST: What kinds of illnesses would you be dealing with?
Mr. Nash: At the moment, we have received approval for sale in Europe
for the delivery of chemotherapeutic agents to deal with solid-tumor
cancer. In the United States we are initiating clinical trials to
deliver genes for a variety of diseases ranging from cancer to
hemophilia to infections diseases including HIV and hepatitis.
Tickers included in this excerpt: GEB
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.